Enteric fever, primarily caused by Salmonella Typhi and Paratyphi, remains a significant global health concern, especially in developing countries. The disease's management is increasingly complex due to emerging antibiotic resistance. This article outlines comprehensive strategies for effective enteric fever management.
Early diagnosis is crucial for effective enteric fever management. The Widal test, though widely used, has limited sensitivity and specificity. More accurate diagnostic methods, such as blood culture and molecular techniques, should be employed whenever possible. Rapid diagnostic tests, like Typhidot and Tubex, can also be useful, particularly in resource-limited settings.
Antibiotic therapy is the mainstay of enteric fever treatment. However, increasing antibiotic resistance, especially to first-line drugs like chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole, necessitates a judicious approach to antibiotic use. Current guidelines recommend third-generation cephalosporins or fluoroquinolones as first-line therapy in most settings. However, local susceptibility patterns should guide antibiotic choice.
Vaccination is a key preventive measure against enteric fever. Currently, two vaccines (Ty21a and Vi polysaccharide) are available and recommended for individuals in high-risk areas and travelers to such regions. However, their use is limited by moderate efficacy and short duration of protection. Continued efforts to develop more effective vaccines are essential.
Public health interventions, such as provision of safe water, adequate sanitation, and food safety measures, play a crucial role in controlling enteric fever. These interventions, combined with vaccination and antibiotic stewardship programs, can significantly reduce the disease burden.
Effective management of enteric fever requires a comprehensive approach, encompassing early diagnosis, appropriate antibiotic therapy, vaccination, and public health measures. Ongoing research into improved diagnostic methods, new antibiotics, and more effective vaccines will further enhance our ability to control this significant global health threat.
1.
A new way to measure suicide risk?
2.
3D virtual staining technology enables non-invasive observation of cancer tissue
3.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
4.
I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.
5.
ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
3.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
4.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
5.
How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
2.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
5.
Navigating the Complexities of Ph Negative ALL - Part IX
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation